Pricing Log in Create free account
Saturday 17 October 2026 Export CLSDQ’s income statement to Excel — free account

Clearside Biomedical, Inc.

CLSDQ Healthcare Biotechnology

Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023. In the quarter to September 2025, revenue fell 80.6%, EPS grew 24.0% and free cash flow grew 8.15%, each against the same quarter a year earlier.

0.25 0.00 0.00%
Market cap
$2.2M
P/E
0.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−22.08
Beneish M
−1.63
Dividend safety
n/a
Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 20.33%

Capital & Financial Ratios $m

Market Cap 2.15
Revenue 3.33
Net Income (26.00)
Free Cash Flow (21.75)
Net Debt (6.80)
Current Ratio 2.98 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.14) (negative: loss-making)
P/S ratio 0.39
P/B ratio 0.00
Past 5Y EPS Growth —
This Y EPS Growth 34.04% (at or above 15%: strong)
Next Y EPS Growth 29.03% (at or above 15%: strong)
Next Y revenue growth 38.22% (at or above 10%: strong)
Next 5Y EPS Growth 22.36% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −1.2×, against a ten-year median of 15.9×; over the ten years it ranged from −13.7× in 2018 to 6,567× in 2017.

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
special payouts not included in total or ratios

Assets vs Liabilities $m

2022 2023 2024 Q'25
Cash 48 29 20 7
Receivables — 0 1 0
Inventory — — — —
Other 0 0 0 —
49 30 21 8
2022 2023 2024 Q'25
Payables 1 2 1 1
ST’ Debt — — — —
Other — — — —
6 7 5 3

Compound Annual Growth %

10y 5y 3y
Sales — (5.20%) (61.68%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 0.00% 0.00%

Revenue $m

Mar Jun Sep Dec Year
’26 2 0 0 — —
’24 0 0 1 0 2
’23 0 1 1 6 8
’22 0 0 0 0 1
’21 0 1 3 26 30
’20 4 0 3 0 8
’19 0 0 0 2 2
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (5) (5) — —
’24 (8) (6) (6) (5) (25)
’23 (7) (5) (6) 0 (18)
’22 4 (5) (6) (6) (13)
’21 (6) (7) (3) 5 (11)
’20 (3) (3) (3) (4) (13)
’19 (13) (10) (6) 2 (27)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (5) (5) — —
’24 (8) (6) (6) (6) (26)
’23 (7) (6) (7) 0 (20)
’22 4 (5) (6) (6) (14)
’21 (6) (7) (3) 5 (11)
’20 (3) (3) (3) (4) (13)
’19 (13) (10) (6) 2 (27)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.65) (0.90) (1.14) — —
’24 (2.55) (1.50) (1.50) (1.50) (7.05)
’23 (2.25) (2.25) (2.25) (1.20) (7.95)
’22 (1.95) (1.95) (1.95) (2.40) (8.25)
’21 (1.95) (1.65) (1.20) 4.65 0.09
’20 (1.05) (1.95) (0.75) (2.10) (5.85)
’19 (6.75) (2.25) (2.55) (1.05) (12.14)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Trend 2025e 2026e 2027e
Price, $
Price, $ Low — 84.75 81.60 14.85 8.40 16.50 33.15 14.70 9.75 12.02

Analyst estimates 2025–2027

Powerpack
High — 376.20 156.92 229.94 59.25 61.95 115.95 44.25 27.75 31.80
People
People Employees — 24 34 50 33 33 34 36 30 32
Revenue/emp, $m — 0.02 0.01 0.00 0.07 0.24 0.87 0.04 0.27 0.05
Income, $m
Income, $m Revenue — 1 0 0 2 8 30 1 8 2
Gross margin, % — 100.00 100.00 100.00 100.00 100.00 100.00 84.63 95.68 91.05
EBT — (26) (59) (83) (31) (18) 0 (33) (32) (34)
EBT margin, % — (4,977.31) (17,094.20) (276,060.00) (1,416.01) (230.68) 1.27 (2,482.82) (394.91) (2,064.42)
Net income — (26) (59) (83) (31) (18) 0 (33) (32) (34)
Depreciation — 0 0 0 0 0 0 0 0 0
Per share, $
Per share, $ Revenue — 0.59 0.20 0.01 0.85 2.54 7.58 0.33 2.00 0.34
Earnings — (29.53) (34.93) (40.33) (12.14) (5.85) 0.10 (8.25) (7.95) (7.05)
Cash flow — (25.97) (30.26) (38.63) (10.63) (4.23) (2.75) (3.33) (4.40) (5.02)
Capex — 0.00 (0.18) (0.04) (0.01) (0.02) 0.00 (0.06) (0.43) (0.20)
Free cash flow — (25.97) (30.44) (38.68) (10.64) (4.25) (2.75) (3.39) (4.83) (5.22)
Book value — 81.94 12.68 11.52 4.38 2.83 9.73 2.64 (3.86) (7.89)
Shares, m — 1 2 2 3 3 4 4 4 5
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — 236.37 527.78 95.37 50.97 16.15 5.44 55.17 9.70 42.16
P/B — 1.72 8.50 1.39 9.93 14.55 4.24 6.90 0.00 0.00
EV/Sales — 94.74 441.89 5.80 42.94 14.13 4.46 19.84 6.35 30.95
EV/FCF — (2.17) (2.97) (0.03) (3.44) (8.47) (12.22) (1.93) (2.62) (2.01)
Cash, $m
Cash, $m Operating cash flow — (23) (51) (79) (27) (13) (11) (13) (18) (25)
Capex — 0 0 0 0 0 — 0 (2) (1)
Free cash flow — (23) (51) (79) (27) (13) (11) (14) (20) (26)
Balance, $m
Balance, $m Working capital — 79 26 32 14 8 37 44 23 16
Total debt — 8 8 10 5 1 1 35 — —
Net debt — (76) (30) (31) (17) (16) (30) (48) (29) (20)
Shareholders’ equity — 72 21 24 11 9 38 11 (16) (39)
Returns, %
Returns, % ROA — (48.89) (94.13) (195.76) (86.80) (79.01) 1.21 (69.95) (76.15) (116.16)
ROIC — 0.00 0.00 0.00 0.00 0.00 (5.20) 0.00 0.00 0.00
ROE — (147.90) (126.73) (367.79) (176.96) (182.83) 1.61 (135.63) 1,224.69 125.45
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2024 · latest quarter Sep 2025

Charts ten years each

Clearside Biomedical, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MTNB Matinas Biopharma Holdings, Inc. $2.4M — (loss-making) — (loss-making) +365,433.33% (above 0%: growing) n/m +9.15% (above 0%: growing) 0.00% 0.00% Compare
BPTSY Biophytis SA Sponsored ADR $2.4M — (loss-making) — — n/m +53.15% (above 0%: growing) 0.00% — Compare
WINT Windtree Therapeutics, Inc. $2.4M — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m +1.12% (above 0%: growing) 0.00% 0.00% Compare
KAPA Kairos Pharma, Ltd. $2.3M — (loss-making) — — n/m −25.71% (below 0%: shrinking) — 0.00% Compare
VRAX Virax Biolabs Group Limited $2.2M — (loss-making) — (loss-making) — −855.56% (below 0%: shrinking) +32.24% (above 0%: growing) (53.57%) 0.00% Compare
CLSDQ Clearside Biomedical, Inc. $2.2M — (loss-making) — (loss-making) −80.64% (below 0%: shrinking) n/m +8.15% (above 0%: growing) 100.00% (3,502.49%)
BRTX Biorestorative Therapies, Inc. $2.0M — (loss-making) — (loss-making) −7.20% (below 0%: shrinking) n/m −35.26% (below 0%: shrinking) 68.10% (14,593.53%) Compare
PPBT Purple Biotech Ltd. Sponsored ADR $2.0M — (loss-making) — (loss-making) — n/m −62.10% (below 0%: shrinking) 0.00% 0.00% Compare
OGEN Oragenics, Inc. $2.0M 0.4× — (loss-making) −75.33% (below 0%: shrinking) n/m −66.37% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $2.2M — — −41.26% — −12.29% 0.00% 0.00%

All 614 Biotechnology stocks →

Clearside Biomedical, Inc. (CLSDQ) key facts

  • Concern: Clearside Biomedical, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.7 million, down 79.8% from fiscal 2023.
  • Clearside Biomedical, Inc. (CLSDQ) is a Biotechnology company in the Healthcare sector.
  • As of July 22, 2026, CLSDQ traded at $0.25, a market capitalization of $2.2 million.
  • Return on equity was 125.5% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −22.08 (distress zone) for fiscal 2024.

Source: company filings (standardised) and stockrow calculations.

Clearside Biomedical, Inc. (CLSDQ) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/CLSDQ · Data as of Sep 30, 2025 · For information only; not investment advice. · © 2026 stockrow.com